{"transactions":[{"id":1168396,"issuer":{"id":80621,"kind":"organization","name":"Paragon 28, Inc.","symbol":"FNA"},"owners":[{"id":80633,"kind":"person","name":"Scanlon Meghan","position":1,"cik":"0001801586","reported_name":"Scanlon Meghan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-04-21T17:00:20.000Z","date":"2025-04-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":42113,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the terms of an Agreement and Plan of Merger, dated January 28, 2025 (the \"Merger Agreement\"), by and among the Issuer, Zimmer Biomet Holdings, Inc., Zimmer, Inc. (\"Parent\"), and Gazelle Merger Sub I, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the \"Effective Time\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $13.00 in cash, without interest (the \"Cash Consideration\") and (ii) one contractual contingent value right (\"CVR\") per share representing the right to receive a contingent payment of up to $1.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent, Equiniti Trust Company, LLC, as rights agent, and, for certain provisions, Zimmer Biomet Holdings, Inc., as guarantor."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each outstanding restricted stock unit solely subject to time-based vesting conditions vested and was canceled, with the holder thereof entitled to receive, with respect to each share of Common Stock underlying such award, (x) the Cash Consideration and (y) one CVR."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-25-056369","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1801586/000095017025056369/ownership.xml","form_type":"4"}},{"id":1507269,"issuer":{"id":80621,"kind":"organization","name":"Paragon 28, Inc.","symbol":"FNA"},"owners":[{"id":80633,"kind":"person","name":"Scanlon Meghan","position":1,"cik":"0001801586","reported_name":"Scanlon Meghan","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-05-21T16:47:42.000Z","date":"2024-05-17","kind":"grant","planned":false,"acquired":true,"shares":15906,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Constitute restricted stock units (\"RSUs\") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the earlier of (i) the first anniversary of grant date and (ii) immediately before the Annual Meeting following the grant date, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":42113,"source":{"system":"sec-edgar","filing":"0001610717-24-000251","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1801586/000161071724000251/form4.xml","form_type":"4"}},{"id":1884767,"issuer":{"id":80621,"kind":"organization","name":"Paragon 28, Inc.","symbol":"FNA"},"owners":[{"id":80633,"kind":"person","name":"Scanlon Meghan","position":1,"cik":"0001801586","reported_name":"Scanlon Meghan","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-05-19T18:30:29.000Z","date":"2023-05-17","kind":"grant","planned":false,"acquired":true,"shares":8361,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Constitute restricted stock units (\"RSUs\") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the earlier of (i) the first anniversary of grant date and (ii) immediately before the Annual Meeting following the grant date, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":26207,"source":{"system":"sec-edgar","filing":"0001610717-23-000056","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1801586/000161071723000056/form4.xml","form_type":"4"}},{"id":2287036,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":80633,"kind":"person","name":"Scanlon Meghan","position":1,"cik":"0001801586","reported_name":"Scanlon Meghan","relationship":{"officer":true,"officer_title":"SVP,Pres,Urology Pelvic Health"}}],"security":"Deferred Stock Units","published_at":"2022-05-02T20:33:30.000Z","date":"2022-05-01","kind":"exercise","acquired":false,"shares":2062,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Shares of common stock will be issued to the reporting person in four equal annual installments beginning on May 1, 2020, the first anniversary of the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Shares of common stock will be issued to the reporting person in four equal annual installments beginning on May 1, 2020, the first anniversary of the date of grant."}],"balance_after":2062,"derivative":{"expiration_date":"2023-05-01","underlying":"Common Stock","underlying_shares":2062},"source":{"system":"sec-edgar","filing":"0001225208-22-006331","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520822006331/doc4.xml","form_type":"4"}},{"id":2287035,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":80633,"kind":"person","name":"Scanlon Meghan","position":1,"cik":"0001801586","reported_name":"Scanlon Meghan","relationship":{"officer":true,"officer_title":"SVP,Pres,Urology Pelvic Health"}}],"security":"Common Stock","published_at":"2022-05-02T20:33:30.000Z","date":"2022-05-01","kind":"tax_withholding","acquired":false,"shares":606,"price":42.11,"value":25518.66,"ownership":{"direct":true},"balance_after":24461,"source":{"system":"sec-edgar","filing":"0001225208-22-006331","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520822006331/doc4.xml","form_type":"4"}},{"id":2287034,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":80633,"kind":"person","name":"Scanlon Meghan","position":1,"cik":"0001801586","reported_name":"Scanlon Meghan","relationship":{"officer":true,"officer_title":"SVP,Pres,Urology Pelvic Health"}}],"security":"Common Stock","published_at":"2022-05-02T20:33:30.000Z","date":"2022-05-01","kind":"exercise","acquired":true,"shares":2062,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."}],"balance_after":25067,"source":{"system":"sec-edgar","filing":"0001225208-22-006331","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520822006331/doc4.xml","form_type":"4"}},{"id":2304760,"issuer":{"id":80621,"kind":"organization","name":"Paragon 28, Inc.","symbol":"FNA"},"owners":[{"id":80633,"kind":"person","name":"Scanlon Meghan","position":1,"cik":"0001801586","reported_name":"Scanlon Meghan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-04-05T17:10:51.000Z","date":"2022-04-01","kind":"grant","acquired":true,"shares":17846,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Constitute restricted stock units (\"RSUs\") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs shall vest on each anniversary of April 1, 2022, subject to the Reporting Person's continued service to the issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 17,846 RSUs."}],"balance_after":17846,"source":{"system":"sec-edgar","filing":"0001567619-22-008111","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1801586/000156761922008111/doc1.xml","form_type":"4"}},{"id":2362933,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":80633,"kind":"person","name":"Scanlon Meghan","position":1,"cik":"0001801586","reported_name":"Scanlon Meghan","relationship":{"officer":true,"officer_title":"SVP,Pres,Urology Pelvic Health"}}],"security":"Deferred Stock Units","published_at":"2022-03-02T21:29:53.000Z","date":"2022-02-28","kind":"exercise","acquired":false,"shares":1019,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant."}],"balance_after":0,"derivative":{"expiration_date":"2022-02-28","underlying":"Common Stock","underlying_shares":1019},"source":{"system":"sec-edgar","filing":"0001225208-22-003868","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520822003868/doc4.xml","form_type":"4"}},{"id":2362932,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":80633,"kind":"person","name":"Scanlon Meghan","position":1,"cik":"0001801586","reported_name":"Scanlon Meghan","relationship":{"officer":true,"officer_title":"SVP,Pres,Urology Pelvic Health"}}],"security":"Common Stock","published_at":"2022-03-02T21:29:53.000Z","date":"2022-02-28","kind":"tax_withholding","acquired":false,"shares":300,"price":44.17,"value":13251.0,"ownership":{"direct":true},"balance_after":23005,"source":{"system":"sec-edgar","filing":"0001225208-22-003868","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520822003868/doc4.xml","form_type":"4"}},{"id":2362931,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":80633,"kind":"person","name":"Scanlon Meghan","position":1,"cik":"0001801586","reported_name":"Scanlon Meghan","relationship":{"officer":true,"officer_title":"SVP,Pres,Urology Pelvic Health"}}],"security":"Common Stock","published_at":"2022-03-02T21:29:53.000Z","date":"2022-02-28","kind":"exercise","acquired":true,"shares":1019,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."}],"balance_after":23305,"source":{"system":"sec-edgar","filing":"0001225208-22-003868","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520822003868/doc4.xml","form_type":"4"}},{"id":2376165,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":80633,"kind":"person","name":"Scanlon Meghan","position":1,"cik":"0001801586","reported_name":"Scanlon Meghan","relationship":{"officer":true,"officer_title":"SVP,Pres,Urology Pelvic Health"}}],"security":"Performance Share Units","published_at":"2022-02-24T21:22:00.000Z","date":"2022-02-22","kind":"grant","acquired":true,"shares":8283,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock."},{"field":"shares","element":"transactionShares","label":"F2","text":"On February 17, 2021, the reporting person was awarded a target number of performance share units under the Company's 2021 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2021 adjusted free cash flow measured against its 2021 financial plan over the one-year performance period ending December 31, 2021 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2022, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On February 17, 2021, the reporting person was awarded a target number of performance share units under the Company's 2021 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2021 adjusted free cash flow measured against its 2021 financial plan over the one-year performance period ending December 31, 2021 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2022, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On February 17, 2021, the reporting person was awarded a target number of performance share units under the Company's 2021 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2021 adjusted free cash flow measured against its 2021 financial plan over the one-year performance period ending December 31, 2021 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2022, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On February 17, 2021, the reporting person was awarded a target number of performance share units under the Company's 2021 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2021 adjusted free cash flow measured against its 2021 financial plan over the one-year performance period ending December 31, 2021 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2022, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2023."}],"balance_after":8283,"derivative":{"exercise_date":"2023-12-31","expiration_date":"2023-12-31","underlying":"Common Stock","underlying_shares":8283},"source":{"system":"sec-edgar","filing":"0001225208-22-003300","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520822003300/doc4.xml","form_type":"4"}},{"id":2380095,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":80633,"kind":"person","name":"Scanlon Meghan","position":1,"cik":"0001801586","reported_name":"Scanlon Meghan","relationship":{"officer":true,"officer_title":"SVP,Pres,Urology Pelvic Health"}}],"security":"Deferred Stock Units","published_at":"2022-02-23T21:18:32.000Z","date":"2022-02-21","kind":"exercise","acquired":false,"shares":779,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant."}],"balance_after":779,"derivative":{"expiration_date":"2023-02-21","underlying":"Common Stock","underlying_shares":779},"source":{"system":"sec-edgar","filing":"0001225208-22-003088","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520822003088/doc4.xml","form_type":"4"}},{"id":2380094,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":80633,"kind":"person","name":"Scanlon Meghan","position":1,"cik":"0001801586","reported_name":"Scanlon Meghan","relationship":{"officer":true,"officer_title":"SVP,Pres,Urology Pelvic Health"}}],"security":"Common Stock","published_at":"2022-02-23T21:18:32.000Z","date":"2022-02-21","kind":"tax_withholding","acquired":false,"shares":229,"price":42.55,"value":9743.95,"ownership":{"direct":true},"balance_after":22286,"source":{"system":"sec-edgar","filing":"0001225208-22-003088","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520822003088/doc4.xml","form_type":"4"}},{"id":2380093,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":80633,"kind":"person","name":"Scanlon Meghan","position":1,"cik":"0001801586","reported_name":"Scanlon Meghan","relationship":{"officer":true,"officer_title":"SVP,Pres,Urology Pelvic Health"}}],"security":"Common Stock","published_at":"2022-02-23T21:18:32.000Z","date":"2022-02-21","kind":"exercise","acquired":true,"shares":779,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."}],"balance_after":22515,"source":{"system":"sec-edgar","filing":"0001225208-22-003088","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520822003088/doc4.xml","form_type":"4"}},{"id":2383572,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":80633,"kind":"person","name":"Scanlon Meghan","position":1,"cik":"0001801586","reported_name":"Scanlon Meghan","relationship":{"officer":true,"officer_title":"SVP,Pres,Urology Pelvic Health"}}],"security":"Deferred Stock Units","published_at":"2022-02-22T21:46:56.000Z","date":"2022-02-18","kind":"exercise","acquired":false,"shares":1112,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant."}],"balance_after":2224,"derivative":{"expiration_date":"2024-02-18","underlying":"Common Stock","underlying_shares":1112},"source":{"system":"sec-edgar","filing":"0001225208-22-002933","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520822002933/doc4.xml","form_type":"4"}},{"id":2383571,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":80633,"kind":"person","name":"Scanlon Meghan","position":1,"cik":"0001801586","reported_name":"Scanlon Meghan","relationship":{"officer":true,"officer_title":"SVP,Pres,Urology Pelvic Health"}}],"security":"Restricted Stock Units","published_at":"2022-02-22T21:46:56.000Z","date":"2022-02-17","kind":"exercise","acquired":false,"shares":1583,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant."}],"balance_after":4750,"derivative":{"expiration_date":"2025-02-17","underlying":"Common Stock","underlying_shares":1583},"source":{"system":"sec-edgar","filing":"0001225208-22-002933","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520822002933/doc4.xml","form_type":"4"}},{"id":2383570,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":80633,"kind":"person","name":"Scanlon Meghan","position":1,"cik":"0001801586","reported_name":"Scanlon Meghan","relationship":{"officer":true,"officer_title":"SVP,Pres,Urology Pelvic Health"}}],"security":"Common Stock","published_at":"2022-02-22T21:46:56.000Z","date":"2022-02-18","kind":"tax_withholding","acquired":false,"shares":327,"price":42.55,"value":13913.85,"ownership":{"direct":true},"balance_after":21736,"source":{"system":"sec-edgar","filing":"0001225208-22-002933","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520822002933/doc4.xml","form_type":"4"}},{"id":2383569,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":80633,"kind":"person","name":"Scanlon Meghan","position":1,"cik":"0001801586","reported_name":"Scanlon Meghan","relationship":{"officer":true,"officer_title":"SVP,Pres,Urology Pelvic Health"}}],"security":"Common Stock","published_at":"2022-02-22T21:46:56.000Z","date":"2022-02-18","kind":"exercise","acquired":true,"shares":1112,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."}],"balance_after":22063,"source":{"system":"sec-edgar","filing":"0001225208-22-002933","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520822002933/doc4.xml","form_type":"4"}},{"id":2383568,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":80633,"kind":"person","name":"Scanlon Meghan","position":1,"cik":"0001801586","reported_name":"Scanlon Meghan","relationship":{"officer":true,"officer_title":"SVP,Pres,Urology Pelvic Health"}}],"security":"Common Stock","published_at":"2022-02-22T21:46:56.000Z","date":"2022-02-17","kind":"tax_withholding","acquired":false,"shares":494,"price":42.83,"value":21158.02,"ownership":{"direct":true},"balance_after":20951,"source":{"system":"sec-edgar","filing":"0001225208-22-002933","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520822002933/doc4.xml","form_type":"4"}},{"id":2383567,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":80633,"kind":"person","name":"Scanlon Meghan","position":1,"cik":"0001801586","reported_name":"Scanlon Meghan","relationship":{"officer":true,"officer_title":"SVP,Pres,Urology Pelvic Health"}}],"security":"Common Stock","published_at":"2022-02-22T21:46:56.000Z","date":"2022-02-17","kind":"exercise","acquired":true,"shares":1583,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."}],"balance_after":21445,"source":{"system":"sec-edgar","filing":"0001225208-22-002933","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520822002933/doc4.xml","form_type":"4"}},{"id":2389883,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":80633,"kind":"person","name":"Scanlon Meghan","position":1,"cik":"0001801586","reported_name":"Scanlon Meghan","relationship":{"officer":true,"officer_title":"SVP,Pres,Urology Pelvic Health"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-02-18T01:37:33.000Z","date":"2022-02-16","kind":"grant","acquired":true,"shares":24264,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant."}],"balance_after":24264,"derivative":{"exercise_price":44.19,"expiration_date":"2032-02-16","underlying":"Common Stock","underlying_shares":24264},"source":{"system":"sec-edgar","filing":"0001225208-22-002699","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520822002699/doc4.xml","form_type":"4"}},{"id":2389882,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":80633,"kind":"person","name":"Scanlon Meghan","position":1,"cik":"0001801586","reported_name":"Scanlon Meghan","relationship":{"officer":true,"officer_title":"SVP,Pres,Urology Pelvic Health"}}],"security":"Restricted Stock Units","published_at":"2022-02-18T01:37:33.000Z","date":"2022-02-16","kind":"grant","acquired":true,"shares":8486,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant."}],"balance_after":8486,"derivative":{"expiration_date":"2026-02-16","underlying":"Common Stock","underlying_shares":8486},"source":{"system":"sec-edgar","filing":"0001225208-22-002699","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520822002699/doc4.xml","form_type":"4"}},{"id":2389881,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":80633,"kind":"person","name":"Scanlon Meghan","position":1,"cik":"0001801586","reported_name":"Scanlon Meghan","relationship":{"officer":true,"officer_title":"SVP,Pres,Urology Pelvic Health"}}],"security":"Deferred Stock Units","published_at":"2022-02-18T01:37:33.000Z","date":"2022-02-15","kind":"exercise","acquired":false,"shares":1108,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant."}],"balance_after":1108,"derivative":{"expiration_date":"2023-02-15","underlying":"Common Stock","underlying_shares":1108},"source":{"system":"sec-edgar","filing":"0001225208-22-002699","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520822002699/doc4.xml","form_type":"4"}},{"id":2389880,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":80633,"kind":"person","name":"Scanlon Meghan","position":1,"cik":"0001801586","reported_name":"Scanlon Meghan","relationship":{"officer":true,"officer_title":"SVP,Pres,Urology Pelvic Health"}}],"security":"Common Stock","published_at":"2022-02-18T01:37:33.000Z","date":"2022-02-15","kind":"tax_withholding","acquired":false,"shares":388,"price":44.01,"value":17075.88,"ownership":{"direct":true},"balance_after":19862,"source":{"system":"sec-edgar","filing":"0001225208-22-002699","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520822002699/doc4.xml","form_type":"4"}},{"id":2389879,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":80633,"kind":"person","name":"Scanlon Meghan","position":1,"cik":"0001801586","reported_name":"Scanlon Meghan","relationship":{"officer":true,"officer_title":"SVP,Pres,Urology Pelvic Health"}}],"security":"Common Stock","published_at":"2022-02-18T01:37:33.000Z","date":"2022-02-15","kind":"exercise","acquired":true,"shares":1108,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."}],"balance_after":20250,"source":{"system":"sec-edgar","filing":"0001225208-22-002699","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520822002699/doc4.xml","form_type":"4"}},{"id":2615986,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":80633,"kind":"person","name":"Scanlon Meghan","position":1,"cik":"0001801586","reported_name":"Scanlon Meghan","relationship":{"officer":true,"officer_title":"SVP,Pres,Urology Pelvic Health"}}],"security":"Restricted Stock Units","published_at":"2021-08-04T20:37:28.000Z","date":"2021-08-02","kind":"grant","acquired":true,"shares":15257,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Shares of common stock will be issued to the reporting person in four equal annual installments beginning on August 2, 2022, the first anniversary of the date of grant."}],"balance_after":15257,"derivative":{"expiration_date":"2025-08-02","underlying":"Common Stock","underlying_shares":15257},"source":{"system":"sec-edgar","filing":"0001225208-21-011124","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520821011124/doc4.xml","form_type":"4"}},{"id":2624418,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":80633,"kind":"person","name":"Scanlon Meghan","position":1,"cik":"0001801586","reported_name":"Scanlon Meghan","relationship":{"officer":true,"officer_title":"SVP,Pres,Urology Pelvic Health"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-07-28T00:28:48.000Z","date":"2021-07-27","kind":"exercise","acquired":false,"shares":13850,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Grant to the reporting person of an option to purchase 13,850 shares of common stock vesting in four equal annual installments beginning on July 1, 2017, the first anniversaryof the date of grant."}],"balance_after":0,"derivative":{"exercise_price":23.41,"expiration_date":"2026-07-01","underlying":"Common Stock","underlying_shares":13850},"source":{"system":"sec-edgar","filing":"0001225208-21-010901","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520821010901/doc4.xml","form_type":"4"}},{"id":2624417,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":80633,"kind":"person","name":"Scanlon Meghan","position":1,"cik":"0001801586","reported_name":"Scanlon Meghan","relationship":{"officer":true,"officer_title":"SVP,Pres,Urology Pelvic Health"}}],"security":"Common Stock","published_at":"2021-07-28T00:28:48.000Z","date":"2021-07-27","kind":"sale","acquired":false,"shares":13850,"price":45.01,"value":623388.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sale price. These shares were sold in multiple transactions at $45.00 and $45.02. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":19142,"source":{"system":"sec-edgar","filing":"0001225208-21-010901","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520821010901/doc4.xml","form_type":"4"}},{"id":2624416,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":80633,"kind":"person","name":"Scanlon Meghan","position":1,"cik":"0001801586","reported_name":"Scanlon Meghan","relationship":{"officer":true,"officer_title":"SVP,Pres,Urology Pelvic Health"}}],"security":"Common Stock","published_at":"2021-07-28T00:28:48.000Z","date":"2021-07-27","kind":"exercise","acquired":true,"shares":13850,"price":23.41,"value":324228.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available."}],"balance_after":32992,"source":{"system":"sec-edgar","filing":"0001225208-21-010901","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520821010901/doc4.xml","form_type":"4"}},{"id":2642499,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":80633,"kind":"person","name":"Scanlon Meghan","position":1,"cik":"0001801586","reported_name":"Scanlon Meghan","relationship":{"officer":true,"officer_title":"SVP,Pres,Urology Pelvic Health"}}],"security":"Deferred Stock Units","published_at":"2021-07-06T20:12:45.000Z","date":"2021-07-01","kind":"exercise","acquired":false,"shares":855,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Shares of common stock will be issued to the reporting person in five equal annual installments beginning on July 1, 2017, the first anniversary of the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Shares of common stock will be issued to the reporting person in five equal annual installments beginning on July 1, 2017, the first anniversary of the date of grant."}],"balance_after":0,"derivative":{"expiration_date":"2021-07-01","underlying":"Common Stock","underlying_shares":855},"source":{"system":"sec-edgar","filing":"0001225208-21-010279","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520821010279/doc4.xml","form_type":"4"}},{"id":2642498,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":80633,"kind":"person","name":"Scanlon Meghan","position":1,"cik":"0001801586","reported_name":"Scanlon Meghan","relationship":{"officer":true,"officer_title":"SVP,Pres,Urology Pelvic Health"}}],"security":"Common Stock","published_at":"2021-07-06T20:12:45.000Z","date":"2021-07-01","kind":"tax_withholding","acquired":false,"shares":251,"price":43.36,"value":10883.36,"ownership":{"direct":true},"balance_after":18434,"source":{"system":"sec-edgar","filing":"0001225208-21-010279","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520821010279/doc4.xml","form_type":"4"}},{"id":2642497,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":80633,"kind":"person","name":"Scanlon Meghan","position":1,"cik":"0001801586","reported_name":"Scanlon Meghan","relationship":{"officer":true,"officer_title":"SVP,Pres,Urology Pelvic Health"}}],"security":"Common Stock","published_at":"2021-07-06T20:12:45.000Z","date":"2021-07-01","kind":"exercise","acquired":true,"shares":855,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."}],"balance_after":18685,"source":{"system":"sec-edgar","filing":"0001225208-21-010279","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520821010279/doc4.xml","form_type":"4"}},{"id":2654134,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":80633,"kind":"person","name":"Scanlon Meghan","position":1,"cik":"0001801586","reported_name":"Scanlon Meghan","relationship":{"officer":true,"officer_title":"SVP,Pres,Urology Pelvic Health"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-28T20:18:30.000Z","date":"2021-06-24","kind":"exercise","acquired":false,"shares":16450,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Grant to the reporting person of an option to purchase 18,450 shares of common stock vesting in four equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant."}],"balance_after":0,"derivative":{"exercise_price":17.26,"expiration_date":"2026-02-22","underlying":"Common Stock","underlying_shares":16450},"source":{"system":"sec-edgar","filing":"0001225208-21-009606","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520821009606/doc4.xml","form_type":"4"}},{"id":2654133,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":80633,"kind":"person","name":"Scanlon Meghan","position":1,"cik":"0001801586","reported_name":"Scanlon Meghan","relationship":{"officer":true,"officer_title":"SVP,Pres,Urology Pelvic Health"}}],"security":"Common Stock","published_at":"2021-06-28T20:18:30.000Z","date":"2021-06-24","kind":"sale","acquired":false,"shares":16450,"price":44.03,"value":724293.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan."}],"balance_after":17830,"source":{"system":"sec-edgar","filing":"0001225208-21-009606","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520821009606/doc4.xml","form_type":"4"}},{"id":2654132,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":80633,"kind":"person","name":"Scanlon Meghan","position":1,"cik":"0001801586","reported_name":"Scanlon Meghan","relationship":{"officer":true,"officer_title":"SVP,Pres,Urology Pelvic Health"}}],"security":"Common Stock","published_at":"2021-06-28T20:18:30.000Z","date":"2021-06-24","kind":"exercise","acquired":true,"shares":16450,"price":17.26,"value":283927.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan."}],"balance_after":34280,"source":{"system":"sec-edgar","filing":"0001225208-21-009606","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520821009606/doc4.xml","form_type":"4"}},{"id":2731400,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":80633,"kind":"person","name":"Scanlon Meghan","position":1,"cik":"0001801586","reported_name":"Scanlon Meghan","relationship":{"officer":true,"officer_title":"SVP,Pres,Urology Pelvic Health"}}],"security":"Deferred Stock Units","published_at":"2021-05-04T20:11:42.000Z","date":"2021-05-01","kind":"exercise","acquired":false,"shares":2061,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Shares of common stock will be issued to the reporting person in four equal annual installments beginning on May 1, 2020, the first anniversary of the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Shares of common stock will be issued to the reporting person in four equal annual installments beginning on May 1, 2020, the first anniversary of the date of grant."}],"balance_after":4124,"derivative":{"expiration_date":"2023-05-01","underlying":"Common Stock","underlying_shares":2061},"source":{"system":"sec-edgar","filing":"0001225208-21-007475","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520821007475/doc4.xml","form_type":"4"}},{"id":2731399,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":80633,"kind":"person","name":"Scanlon Meghan","position":1,"cik":"0001801586","reported_name":"Scanlon Meghan","relationship":{"officer":true,"officer_title":"SVP,Pres,Urology Pelvic Health"}}],"security":"Common Stock","published_at":"2021-05-04T20:11:42.000Z","date":"2021-05-01","kind":"tax_withholding","acquired":false,"shares":605,"price":43.6,"value":26378.0,"ownership":{"direct":true},"balance_after":17830,"source":{"system":"sec-edgar","filing":"0001225208-21-007475","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520821007475/doc4.xml","form_type":"4"}},{"id":2731398,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":80633,"kind":"person","name":"Scanlon Meghan","position":1,"cik":"0001801586","reported_name":"Scanlon Meghan","relationship":{"officer":true,"officer_title":"SVP,Pres,Urology Pelvic Health"}}],"security":"Common Stock","published_at":"2021-05-04T20:11:42.000Z","date":"2021-05-01","kind":"exercise","acquired":true,"shares":2061,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."}],"balance_after":18435,"source":{"system":"sec-edgar","filing":"0001225208-21-007475","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520821007475/doc4.xml","form_type":"4"}},{"id":2822977,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":80633,"kind":"person","name":"Scanlon Meghan","position":1,"cik":"0001801586","reported_name":"Scanlon Meghan","relationship":{"officer":true,"officer_title":"SVP,Pres,Urology Pelvic Health"}}],"security":"Deferred Stock Units","published_at":"2021-03-02T21:16:36.000Z","date":"2021-02-28","kind":"exercise","acquired":false,"shares":1018,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant."}],"balance_after":1019,"derivative":{"expiration_date":"2022-02-28","underlying":"Common Stock","underlying_shares":1018},"source":{"system":"sec-edgar","filing":"0001225208-21-004227","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520821004227/doc4.xml","form_type":"4"}},{"id":2822976,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":80633,"kind":"person","name":"Scanlon Meghan","position":1,"cik":"0001801586","reported_name":"Scanlon Meghan","relationship":{"officer":true,"officer_title":"SVP,Pres,Urology Pelvic Health"}}],"security":"Common Stock","published_at":"2021-03-02T21:16:36.000Z","date":"2021-02-28","kind":"tax_withholding","acquired":false,"shares":299,"price":38.78,"value":11595.22,"ownership":{"direct":true},"balance_after":16374,"source":{"system":"sec-edgar","filing":"0001225208-21-004227","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520821004227/doc4.xml","form_type":"4"}},{"id":2822975,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":80633,"kind":"person","name":"Scanlon Meghan","position":1,"cik":"0001801586","reported_name":"Scanlon Meghan","relationship":{"officer":true,"officer_title":"SVP,Pres,Urology Pelvic Health"}}],"security":"Common Stock","published_at":"2021-03-02T21:16:36.000Z","date":"2021-02-28","kind":"exercise","acquired":true,"shares":1018,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."}],"balance_after":16673,"source":{"system":"sec-edgar","filing":"0001225208-21-004227","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520821004227/doc4.xml","form_type":"4"}},{"id":2841188,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":80633,"kind":"person","name":"Scanlon Meghan","position":1,"cik":"0001801586","reported_name":"Scanlon Meghan","relationship":{"officer":true,"officer_title":"SVP,Pres,Urology Pelvic Health"}}],"security":"Performance Share Units","published_at":"2021-02-23T22:15:06.000Z","date":"2021-02-22","kind":"grant","acquired":true,"shares":3940,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock."},{"field":"shares","element":"transactionShares","label":"F5","text":"On February 18, 2020, the reporting person was awarded a target number of performance share units under the Company's 2020 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2020 adjusted free cash flow measured against its 2020 financial plan over the one-year performance period ending December 31, 2020 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2021, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"On February 18, 2020, the reporting person was awarded a target number of performance share units under the Company's 2020 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2020 adjusted free cash flow measured against its 2020 financial plan over the one-year performance period ending December 31, 2020 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2021, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"On February 18, 2020, the reporting person was awarded a target number of performance share units under the Company's 2020 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2020 adjusted free cash flow measured against its 2020 financial plan over the one-year performance period ending December 31, 2020 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2021, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2022."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"On February 18, 2020, the reporting person was awarded a target number of performance share units under the Company's 2020 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2020 adjusted free cash flow measured against its 2020 financial plan over the one-year performance period ending December 31, 2020 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2021, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2022."}],"balance_after":3940,"derivative":{"exercise_date":"2022-12-31","expiration_date":"2022-12-31","underlying":"Common Stock","underlying_shares":3940},"source":{"system":"sec-edgar","filing":"0001225208-21-003528","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520821003528/doc4.xml","form_type":"4"}},{"id":2841187,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":80633,"kind":"person","name":"Scanlon Meghan","position":1,"cik":"0001801586","reported_name":"Scanlon Meghan","relationship":{"officer":true,"officer_title":"SVP,Pres,Urology Pelvic Health"}}],"security":"Deferred Stock Units","published_at":"2021-02-23T22:15:06.000Z","date":"2021-02-22","kind":"exercise","acquired":false,"shares":1159,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant."}],"balance_after":0,"derivative":{"expiration_date":"2021-02-22","underlying":"Common Stock","underlying_shares":1159},"source":{"system":"sec-edgar","filing":"0001225208-21-003528","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520821003528/doc4.xml","form_type":"4"}},{"id":2841186,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":80633,"kind":"person","name":"Scanlon Meghan","position":1,"cik":"0001801586","reported_name":"Scanlon Meghan","relationship":{"officer":true,"officer_title":"SVP,Pres,Urology Pelvic Health"}}],"security":"Deferred Stock Units","published_at":"2021-02-23T22:15:06.000Z","date":"2021-02-21","kind":"exercise","acquired":false,"shares":779,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant."}],"balance_after":1558,"derivative":{"expiration_date":"2023-02-21","underlying":"Common Stock","underlying_shares":779},"source":{"system":"sec-edgar","filing":"0001225208-21-003528","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520821003528/doc4.xml","form_type":"4"}},{"id":2841185,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":80633,"kind":"person","name":"Scanlon Meghan","position":1,"cik":"0001801586","reported_name":"Scanlon Meghan","relationship":{"officer":true,"officer_title":"SVP,Pres,Urology Pelvic Health"}}],"security":"Common Stock","published_at":"2021-02-23T22:15:06.000Z","date":"2021-02-22","kind":"tax_withholding","acquired":false,"shares":338,"price":39.2,"value":13249.6,"ownership":{"direct":true},"balance_after":15655,"source":{"system":"sec-edgar","filing":"0001225208-21-003528","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520821003528/doc4.xml","form_type":"4"}},{"id":2841184,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":80633,"kind":"person","name":"Scanlon Meghan","position":1,"cik":"0001801586","reported_name":"Scanlon Meghan","relationship":{"officer":true,"officer_title":"SVP,Pres,Urology Pelvic Health"}}],"security":"Common Stock","published_at":"2021-02-23T22:15:06.000Z","date":"2021-02-22","kind":"exercise","acquired":true,"shares":1159,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."}],"balance_after":15993,"source":{"system":"sec-edgar","filing":"0001225208-21-003528","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520821003528/doc4.xml","form_type":"4"}},{"id":2841183,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":80633,"kind":"person","name":"Scanlon Meghan","position":1,"cik":"0001801586","reported_name":"Scanlon Meghan","relationship":{"officer":true,"officer_title":"SVP,Pres,Urology Pelvic Health"}}],"security":"Common Stock","published_at":"2021-02-23T22:15:06.000Z","date":"2021-02-21","kind":"tax_withholding","acquired":false,"shares":223,"price":38.03,"value":8480.69,"ownership":{"direct":true},"balance_after":14834,"source":{"system":"sec-edgar","filing":"0001225208-21-003528","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520821003528/doc4.xml","form_type":"4"}},{"id":2841182,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":80633,"kind":"person","name":"Scanlon Meghan","position":1,"cik":"0001801586","reported_name":"Scanlon Meghan","relationship":{"officer":true,"officer_title":"SVP,Pres,Urology Pelvic Health"}}],"security":"Common Stock","published_at":"2021-02-23T22:15:06.000Z","date":"2021-02-21","kind":"exercise","acquired":true,"shares":779,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."}],"balance_after":15057,"source":{"system":"sec-edgar","filing":"0001225208-21-003528","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520821003528/doc4.xml","form_type":"4"}},{"id":2847437,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":80633,"kind":"person","name":"Scanlon Meghan","position":1,"cik":"0001801586","reported_name":"Scanlon Meghan","relationship":{"officer":true,"officer_title":"SVP,Pres,Urology Pelvic Health"}}],"security":"Deferred Stock Units","published_at":"2021-02-19T21:25:11.000Z","date":"2021-02-18","kind":"exercise","acquired":false,"shares":1111,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant."}],"balance_after":3336,"derivative":{"expiration_date":"2024-02-18","underlying":"Common Stock","underlying_shares":1111},"source":{"system":"sec-edgar","filing":"0001225208-21-003183","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520821003183/doc4.xml","form_type":"4"}},{"id":2847436,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":80633,"kind":"person","name":"Scanlon Meghan","position":1,"cik":"0001801586","reported_name":"Scanlon Meghan","relationship":{"officer":true,"officer_title":"SVP,Pres,Urology Pelvic Health"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-02-19T21:25:11.000Z","date":"2021-02-17","kind":"grant","acquired":true,"shares":20368,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant."}],"balance_after":20368,"derivative":{"exercise_price":37.5,"expiration_date":"2031-02-17","underlying":"Common Stock","underlying_shares":20368},"source":{"system":"sec-edgar","filing":"0001225208-21-003183","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520821003183/doc4.xml","form_type":"4"}},{"id":2847435,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":80633,"kind":"person","name":"Scanlon Meghan","position":1,"cik":"0001801586","reported_name":"Scanlon Meghan","relationship":{"officer":true,"officer_title":"SVP,Pres,Urology Pelvic Health"}}],"security":"Restricted Stock Units","published_at":"2021-02-19T21:25:11.000Z","date":"2021-02-17","kind":"grant","acquired":true,"shares":6333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant."}],"balance_after":6333,"derivative":{"expiration_date":"2025-02-17","underlying":"Common Stock","underlying_shares":6333},"source":{"system":"sec-edgar","filing":"0001225208-21-003183","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520821003183/doc4.xml","form_type":"4"}},{"id":2847434,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":80633,"kind":"person","name":"Scanlon Meghan","position":1,"cik":"0001801586","reported_name":"Scanlon Meghan","relationship":{"officer":true,"officer_title":"SVP,Pres,Urology Pelvic Health"}}],"security":"Common Stock","published_at":"2021-02-19T21:25:11.000Z","date":"2021-02-18","kind":"tax_withholding","acquired":false,"shares":372,"price":37.52,"value":13957.44,"ownership":{"direct":true},"balance_after":14278,"source":{"system":"sec-edgar","filing":"0001225208-21-003183","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520821003183/doc4.xml","form_type":"4"}},{"id":2847433,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":80633,"kind":"person","name":"Scanlon Meghan","position":1,"cik":"0001801586","reported_name":"Scanlon Meghan","relationship":{"officer":true,"officer_title":"SVP,Pres,Urology Pelvic Health"}}],"security":"Common Stock","published_at":"2021-02-19T21:25:11.000Z","date":"2021-02-18","kind":"exercise","acquired":true,"shares":1111,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."}],"balance_after":14650,"source":{"system":"sec-edgar","filing":"0001225208-21-003183","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520821003183/doc4.xml","form_type":"4"}},{"id":2856248,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":80633,"kind":"person","name":"Scanlon Meghan","position":1,"cik":"0001801586","reported_name":"Scanlon Meghan","relationship":{"officer":true,"officer_title":"SVP,Pres,Urology Pelvic Health"}}],"security":"Deferred Stock Units","published_at":"2021-02-17T21:16:42.000Z","date":"2021-02-15","kind":"exercise","acquired":false,"shares":1107,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant."}],"balance_after":2216,"derivative":{"expiration_date":"2023-02-15","underlying":"Common Stock","underlying_shares":1107},"source":{"system":"sec-edgar","filing":"0001225208-21-002711","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520821002711/doc4.xml","form_type":"4"}},{"id":2856247,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":80633,"kind":"person","name":"Scanlon Meghan","position":1,"cik":"0001801586","reported_name":"Scanlon Meghan","relationship":{"officer":true,"officer_title":"SVP,Pres,Urology Pelvic Health"}}],"security":"Common Stock","published_at":"2021-02-17T21:16:42.000Z","date":"2021-02-15","kind":"tax_withholding","acquired":false,"shares":388,"price":38.39,"value":14895.32,"ownership":{"direct":true},"balance_after":13539,"source":{"system":"sec-edgar","filing":"0001225208-21-002711","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520821002711/doc4.xml","form_type":"4"}},{"id":2856246,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":80633,"kind":"person","name":"Scanlon Meghan","position":1,"cik":"0001801586","reported_name":"Scanlon Meghan","relationship":{"officer":true,"officer_title":"SVP,Pres,Urology Pelvic Health"}}],"security":"Common Stock","published_at":"2021-02-17T21:16:42.000Z","date":"2021-02-15","kind":"exercise","acquired":true,"shares":1107,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."}],"balance_after":13927,"source":{"system":"sec-edgar","filing":"0001225208-21-002711","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520821002711/doc4.xml","form_type":"4"}},{"id":3089972,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":80633,"kind":"person","name":"Scanlon Meghan","position":1,"cik":"0001801586","reported_name":"Scanlon Meghan","relationship":{"officer":true,"officer_title":"SVP,Pres,Urology Pelvic Health"}}],"security":"Deferred Stock Units","published_at":"2020-07-09T14:13:08.000Z","date":"2020-07-01","kind":"exercise","acquired":false,"shares":854,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Shares of common stock will be issued to the reporting person in five equal annual installments beginning on July 1, 2017, the first anniversary of the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Shares of common stock will be issued to the reporting person in five equal annual installments beginning on July 1, 2017, the first anniversary of the date of grant."}],"balance_after":855,"derivative":{"expiration_date":"2021-07-01","underlying":"Common Stock","underlying_shares":854},"source":{"system":"sec-edgar","filing":"0001225208-20-009668","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520820009668/doc4.xml","form_type":"4"}},{"id":3089971,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":80633,"kind":"person","name":"Scanlon Meghan","position":1,"cik":"0001801586","reported_name":"Scanlon Meghan","relationship":{"officer":true,"officer_title":"SVP,Pres,Urology Pelvic Health"}}],"security":"Common Stock","published_at":"2020-07-09T14:13:08.000Z","date":"2020-07-01","kind":"tax_withholding","acquired":false,"shares":260,"price":35.28,"value":9172.8,"ownership":{"direct":true},"balance_after":12269,"source":{"system":"sec-edgar","filing":"0001225208-20-009668","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520820009668/doc4.xml","form_type":"4"}},{"id":3089970,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":80633,"kind":"person","name":"Scanlon Meghan","position":1,"cik":"0001801586","reported_name":"Scanlon Meghan","relationship":{"officer":true,"officer_title":"SVP,Pres,Urology Pelvic Health"}}],"security":"Common Stock","published_at":"2020-07-09T14:13:08.000Z","date":"2020-07-01","kind":"exercise","acquired":true,"shares":854,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."}],"balance_after":12529,"source":{"system":"sec-edgar","filing":"0001225208-20-009668","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520820009668/doc4.xml","form_type":"4"}},{"id":3164309,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":80633,"kind":"person","name":"Scanlon Meghan","position":1,"cik":"0001801586","reported_name":"Scanlon Meghan","relationship":{"officer":true,"officer_title":"SVP,Pres,Urology Pelvic Health"}}],"security":"Deferred Stock Units","published_at":"2020-05-04T20:20:53.000Z","date":"2020-05-01","kind":"exercise","acquired":false,"shares":2061,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Shares of common stock will be issued to the reporting person in four equal annual installments beginning on May 1, 2020, the first anniversary of the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Shares of common stock will be issued to the reporting person in four equal annual installments beginning on May 1, 2020, the first anniversary of the date of grant."}],"balance_after":6185,"derivative":{"expiration_date":"2023-05-01","underlying":"Common Stock","underlying_shares":2061},"source":{"system":"sec-edgar","filing":"0001225208-20-007000","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520820007000/doc4.xml","form_type":"4"}},{"id":3164308,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":80633,"kind":"person","name":"Scanlon Meghan","position":1,"cik":"0001801586","reported_name":"Scanlon Meghan","relationship":{"officer":true,"officer_title":"SVP,Pres,Urology Pelvic Health"}}],"security":"Common Stock","published_at":"2020-05-04T20:20:53.000Z","date":"2020-05-01","kind":"tax_withholding","acquired":false,"shares":626,"price":35.99,"value":22529.74,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available."}],"balance_after":11675,"source":{"system":"sec-edgar","filing":"0001225208-20-007000","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520820007000/doc4.xml","form_type":"4"}},{"id":3164307,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":80633,"kind":"person","name":"Scanlon Meghan","position":1,"cik":"0001801586","reported_name":"Scanlon Meghan","relationship":{"officer":true,"officer_title":"SVP,Pres,Urology Pelvic Health"}}],"security":"Common Stock","published_at":"2020-05-04T20:20:53.000Z","date":"2020-05-01","kind":"exercise","acquired":true,"shares":2061,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available."}],"balance_after":12301,"source":{"system":"sec-edgar","filing":"0001225208-20-007000","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520820007000/doc4.xml","form_type":"4"}},{"id":3235061,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":80633,"kind":"person","name":"Scanlon Meghan","position":1,"cik":"0001801586","reported_name":"Scanlon Meghan","relationship":{"officer":true,"officer_title":"SVP,Pres,Urology Pelvic Health"}}],"security":"Deferred Stock Units","published_at":"2020-03-03T21:15:10.000Z","date":"2020-02-28","kind":"exercise","acquired":false,"shares":1018,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant."}],"balance_after":2037,"derivative":{"expiration_date":"2022-02-28","underlying":"Common Stock","underlying_shares":1018},"source":{"system":"sec-edgar","filing":"0001225208-20-004165","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520820004165/doc4.xml","form_type":"4"}},{"id":3235060,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":80633,"kind":"person","name":"Scanlon Meghan","position":1,"cik":"0001801586","reported_name":"Scanlon Meghan","relationship":{"officer":true,"officer_title":"SVP,Pres,Urology Pelvic Health"}}],"security":"Common Stock","published_at":"2020-03-03T21:15:10.000Z","date":"2020-02-28","kind":"tax_withholding","acquired":false,"shares":309,"price":37.39,"value":11553.51,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available."}],"balance_after":10240,"source":{"system":"sec-edgar","filing":"0001225208-20-004165","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520820004165/doc4.xml","form_type":"4"}},{"id":3235059,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":80633,"kind":"person","name":"Scanlon Meghan","position":1,"cik":"0001801586","reported_name":"Scanlon Meghan","relationship":{"officer":true,"officer_title":"SVP,Pres,Urology Pelvic Health"}}],"security":"Common Stock","published_at":"2020-03-03T21:15:10.000Z","date":"2020-02-28","kind":"exercise","acquired":true,"shares":1018,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available."}],"balance_after":10549,"source":{"system":"sec-edgar","filing":"0001225208-20-004165","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520820004165/doc4.xml","form_type":"4"}},{"id":3254593,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":80633,"kind":"person","name":"Scanlon Meghan","position":1,"cik":"0001801586","reported_name":"Scanlon Meghan","relationship":{"officer":true,"officer_title":"SVP,Pres,Urology Pelvic Health"}}],"security":"Deferred Stock Units","published_at":"2020-02-24T22:15:04.000Z","date":"2020-02-23","kind":"exercise","acquired":false,"shares":1227,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 23, 2016, the first anniversary of the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 23, 2016, the first anniversary of the date of grant."}],"balance_after":0,"derivative":{"expiration_date":"2020-02-23","underlying":"Common Stock","underlying_shares":1227},"source":{"system":"sec-edgar","filing":"0001225208-20-003299","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520820003299/doc4.xml","form_type":"4"}},{"id":3254592,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":80633,"kind":"person","name":"Scanlon Meghan","position":1,"cik":"0001801586","reported_name":"Scanlon Meghan","relationship":{"officer":true,"officer_title":"SVP,Pres,Urology Pelvic Health"}}],"security":"Deferred Stock Units","published_at":"2020-02-24T22:15:04.000Z","date":"2020-02-22","kind":"exercise","acquired":false,"shares":1159,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant."}],"balance_after":1159,"derivative":{"expiration_date":"2021-02-22","underlying":"Common Stock","underlying_shares":1159},"source":{"system":"sec-edgar","filing":"0001225208-20-003299","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520820003299/doc4.xml","form_type":"4"}},{"id":3254591,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":80633,"kind":"person","name":"Scanlon Meghan","position":1,"cik":"0001801586","reported_name":"Scanlon Meghan","relationship":{"officer":true,"officer_title":"SVP,Pres,Urology Pelvic Health"}}],"security":"Deferred Stock Units","published_at":"2020-02-24T22:15:04.000Z","date":"2020-02-21","kind":"exercise","acquired":false,"shares":778,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant."}],"balance_after":2337,"derivative":{"expiration_date":"2023-02-21","underlying":"Common Stock","underlying_shares":778},"source":{"system":"sec-edgar","filing":"0001225208-20-003299","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520820003299/doc4.xml","form_type":"4"}},{"id":3254590,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":80633,"kind":"person","name":"Scanlon Meghan","position":1,"cik":"0001801586","reported_name":"Scanlon Meghan","relationship":{"officer":true,"officer_title":"SVP,Pres,Urology Pelvic Health"}}],"security":"Common Stock","published_at":"2020-02-24T22:15:04.000Z","date":"2020-02-23","kind":"tax_withholding","acquired":false,"shares":359,"price":42.62,"value":15300.58,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available."}],"balance_after":9531,"source":{"system":"sec-edgar","filing":"0001225208-20-003299","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520820003299/doc4.xml","form_type":"4"}},{"id":3254589,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":80633,"kind":"person","name":"Scanlon Meghan","position":1,"cik":"0001801586","reported_name":"Scanlon Meghan","relationship":{"officer":true,"officer_title":"SVP,Pres,Urology Pelvic Health"}}],"security":"Common Stock","published_at":"2020-02-24T22:15:04.000Z","date":"2020-02-23","kind":"exercise","acquired":true,"shares":1227,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available."}],"balance_after":9890,"source":{"system":"sec-edgar","filing":"0001225208-20-003299","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520820003299/doc4.xml","form_type":"4"}},{"id":3254588,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":80633,"kind":"person","name":"Scanlon Meghan","position":1,"cik":"0001801586","reported_name":"Scanlon Meghan","relationship":{"officer":true,"officer_title":"SVP,Pres,Urology Pelvic Health"}}],"security":"Common Stock","published_at":"2020-02-24T22:15:04.000Z","date":"2020-02-22","kind":"tax_withholding","acquired":false,"shares":331,"price":42.62,"value":14107.22,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available."}],"balance_after":8663,"source":{"system":"sec-edgar","filing":"0001225208-20-003299","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520820003299/doc4.xml","form_type":"4"}},{"id":3254587,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":80633,"kind":"person","name":"Scanlon Meghan","position":1,"cik":"0001801586","reported_name":"Scanlon Meghan","relationship":{"officer":true,"officer_title":"SVP,Pres,Urology Pelvic Health"}}],"security":"Common Stock","published_at":"2020-02-24T22:15:04.000Z","date":"2020-02-22","kind":"exercise","acquired":true,"shares":1159,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available."}],"balance_after":8994,"source":{"system":"sec-edgar","filing":"0001225208-20-003299","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520820003299/doc4.xml","form_type":"4"}},{"id":3254586,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":80633,"kind":"person","name":"Scanlon Meghan","position":1,"cik":"0001801586","reported_name":"Scanlon Meghan","relationship":{"officer":true,"officer_title":"SVP,Pres,Urology Pelvic Health"}}],"security":"Common Stock","published_at":"2020-02-24T22:15:04.000Z","date":"2020-02-21","kind":"tax_withholding","acquired":false,"shares":264,"price":42.62,"value":11251.68,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available."}],"balance_after":7835,"source":{"system":"sec-edgar","filing":"0001225208-20-003299","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520820003299/doc4.xml","form_type":"4"}},{"id":3254585,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":80633,"kind":"person","name":"Scanlon Meghan","position":1,"cik":"0001801586","reported_name":"Scanlon Meghan","relationship":{"officer":true,"officer_title":"SVP,Pres,Urology Pelvic Health"}}],"security":"Common Stock","published_at":"2020-02-24T22:15:04.000Z","date":"2020-02-21","kind":"exercise","acquired":true,"shares":778,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available."}],"balance_after":8099,"source":{"system":"sec-edgar","filing":"0001225208-20-003299","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520820003299/doc4.xml","form_type":"4"}},{"id":3264763,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":80633,"kind":"person","name":"Scanlon Meghan","position":1,"cik":"0001801586","reported_name":"Scanlon Meghan","relationship":{"officer":true,"officer_title":"SVP,Pres,Urology Pelvic Health"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-02-19T22:33:14.000Z","date":"2020-02-18","kind":"grant","acquired":true,"shares":16592,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant."}],"balance_after":16592,"derivative":{"exercise_price":42.16,"expiration_date":"2030-02-18","underlying":"Common Stock","underlying_shares":16592},"source":{"system":"sec-edgar","filing":"0001225208-20-002844","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520820002844/doc4.xml","form_type":"4"}},{"id":3264762,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":80633,"kind":"person","name":"Scanlon Meghan","position":1,"cik":"0001801586","reported_name":"Scanlon Meghan","relationship":{"officer":true,"officer_title":"SVP,Pres,Urology Pelvic Health"}}],"security":"Deferred Stock Units","published_at":"2020-02-19T22:33:14.000Z","date":"2020-02-18","kind":"grant","acquired":true,"shares":4447,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant."}],"balance_after":4447,"derivative":{"expiration_date":"2024-02-18","underlying":"Common Stock","underlying_shares":4447},"source":{"system":"sec-edgar","filing":"0001225208-20-002844","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520820002844/doc4.xml","form_type":"4"}}]}